Sandoz receives FDA approval for Prolia, Xgeva biosimilars
Sandoz has obtained the Food and Drug Administration’s clearance for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the only FDA-approved denosumab biosimilars, to treat all indications of Amgen's Xgeva and Prolia.
Keren Haruvi, president of Sandoz North America, said, "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events, which are disease states that can profoundly reduce quality of life for patients. I am proud that Sandoz continues to pioneer access to these life-changing medicines for the patients who need them most."
Wyost is approved to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. It's designed to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy.
Jubbonti is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
[Read more: Novartis completes Spin-off of Sandoz generics, biosimilars business]
Osteoporosis is a bone disease that develops when bone mineral density and bone mass decrease or when bone strength and structure change. People living with osteoporosis typically do not have symptoms and might not know they have the disease until they experience a fracture.
Wyost and Jubbonti have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines.
Given ongoing patent litigation around these products, Sandoz will not comment on anticipated launch timing or other launch details at this time.
[Read more: Sandoz closing Fougera facilities on Long Island, N.Y.]